MedWatch

GN Hearing downgrades organic growth forecast

Wednesday evening, the Danish hearing aid manufacturer follows up on its Q2 report by its downgrading full-year guidance for organic growth.

Photo: GN Store Nord / PR

Having already published its second-quarter financial statement ahead of schedule Wednesday evening, the hearing aid company now lowers its organic growth outlook for the full year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs